OpenAI has entered a new collaboration with Lundbeck to expand the use of large language models in pharmaceutical research and drug development.
Lundbeck, a global biopharmaceutical company with operations in Bothell, Washington, will deploy ChatGPT Enterprise across its global teams to improve research productivity and accelerate progress in brain disorder studies, including migraine, depression and anxiety. “By integrating AI into our daily processes, we’re unlocking new levels of efficiency and innovation,” said Claus Thomsen, Lundbeck’s head of global IT. The rollout follows a successful pilot demonstrating improved research speed and analysis quality.
Lundbeck’s collaboration with OpenAI underscores the company’s commitment to advancing neuroscience and highlights the growing role of AI-enabled discovery in Washington state’s life sciences industry.